智通财经APP获悉，Summit Therapeutics公司今天宣布，与辉瑞(PFE.US)开展临床试验合作，评估在研靶向PD-1/VEGF的双特异性抗体ivonescimab，与辉瑞的多种抗体偶联药物(ADCs)联用，治疗多种实体瘤的效果。
Ivonescimab为靶向PD-1和VEGF的双特异性抗体，最初由康方生物开发，可阻断PD-1与PD-L1和PD-L2的结合，同时阻断VEGF与VEGF受体的结合。康方生物(09926)公开资料指出，鉴于VEGF和PD-1在肿瘤微环境中的共表达，与联合疗法相比，该产品作为单一药物同时阻断这两个靶点，可能会更有效地阻断这两个信号通路，增强抗肿瘤活性。此外，与联合疗法相比，ivonescimab安全性优势显著，与VEGF靶点相关的毒副作用大幅度降低。
在2024年世界肺癌大会(WCLC 2024)上公布的3期临床试验HARMONi-2的主要分析数据显示，ivonescimab与获批重磅免疫检查点抑制剂相比，作为一线疗法，显著降低了PD-L1阳性晚期非小细胞肺癌(NSCLC)患者疾病进展或死亡的风险。行业媒体Evaluate在今年年初发布的2025年生物医药产业趋势报告中将其列为2025年潜在重磅的10项研发管线之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.